# Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)

> **NCT07688980** · PHASE1 · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 92 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **COMBINATION_PRODUCT:** Anifrolumab: SC formulation via AI
- **COMBINATION_PRODUCT:** Anifrolumab: IV formulation
- **COMBINATION_PRODUCT:** Anifrolumab: SC formulation via aPFS

## Key facts

- **NCT ID:** NCT07688980
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2029-04-13
- **Final completion:** 2030-06-14
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688980, "Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07688980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*